Introduction
============

Diabetes is a rapidly growing health problem worldwide, related in part to improved living conditions and increasing rate of obesity ([@b77]). It is estimated that approximately 5% of people in the general population of most industrialized societies have diabetes mellitus and that an additional 3%--5% have either undiagnosed diabetes or impaired glucose tolerance. According to the World Health Organization, worldwide the number of people living with diabetes is projected to increased from 172 million in 2000 (prevalence: 2.8%) to 366 million (prevalence: 4.4%) in 2030 ([@b76]). Hypertension is a common co-morbid condition in diabetes and found in 20%--60% of patients with diabetes ([@b8]). Prevalence of hypertension in the diabetic population is 1.5--3 times higher than in the age- and weight-adjusted non-diabetic group ([@b36]). In type 2 diabetes, hypertension is often present as a part of metabolic syndrome, while in type 1 diabetes it may herald the onset of diabetic kidney disease. The hypertensive diabetic individuals are at a 2- to 4-fold greater risk of vascular complications, such as coronary artery disease, cerebrovascular accident, and death compared with age-matched control subjects and with the patients with type 2 diabetes mellitus but normal blood pressure. Similarly, they also have a 7-fold greater risk of progression to end stage renal disease (ESRD) ([@b47]; [@b14]). Reduction of high blood pressure reduces cardiovascular morbidity and mortality and delays the progression to ESRD. Indeed, various studies has shown that lowering blood pressure in high risk patients with diabetes reduces overall mortality ([@b31]; [@b71]; [@b73]), death from stroke ([@b22]), and cardiovascular events ([@b31]; [@b66]) and slows the progression of renal disease in patients with type 2 diabetes mellitus ([@b18]; [@b46]; [@b15]). Consensus statements and guidelines from various international authorities recommend initiation of pharmacological therapy with the goal of reduction of blood pressure to \<130/80 mmHg ([@b43]; [@b8]) and/or \<130/85 mmHg ([@b20]) and consider diabetes as a risk equivalent similar to history of myocardial infarction ([@b20]) because of the increased risk of cardiovascular events in these groups of patients. Evidence has shown that achieving this goal requires multiple drug antihypertensive therapy. Indeed, because of the fact that blood pressure reduction to recommended goal is often difficult to achieve with monotherapy, the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC) ([@b20]) suggests initial use of a two-drug combination, even in non-diabetic patients. Greater efficacy is likely to be achieved when two or more antihypertensive agents with complementary modes of action are used to reduce blood pressure. This approach is also likely to reduce adverse effects of drugs, as both drugs can be given at a lower dose than either drug as monotherapy. In addition, combination of two fixed-dose agents in a single capsule or tablet is expected to increase compliance ([@b59]). In treatment of hypertensive diabetic patients adverse effects on metabolic control and insulin sensitivity is an issue to be considered. Calcium channel blockers and angiotensin-converting enzyme (ACE) inhibitors are considered lack of undesirable effect on glucose tolerance and insulin sensitivity; rather potentially improve insulin sensitivity ([@b64]; [@b35]).

Trandolapril/verapamil sustained released (SR) is a fixed-dose combination of trandolapril, and a sustained release formulation of verapamil ([@b3]). This article provides an overview of trandolapril/verapamil SR in the treatment of hypertensive diabetic patients and its effectiveness on reduction of microalbuminuria in hypertensive type 2 diabetic patients.

Pharmacodynamics properties of trandolapril/verapamil SR
========================================================

Trandolapril is an ethyl ester pro-drug of a nonsufyldril ACE inhibitor. It is converted to trandolaprilat by de-esterfication. The active metabolite is 8 times more active as an inhibitor of ACE. Trandolapril inhibits the circulating and tissue ACE, leading to inhibition of conversion of angiotensin I to angiotensin II that results in a decrease in vasoconstriction, a decrease in aldoesteron secretion, and an increase in plasma renin ([@b42]). Although, the principal mechanism of trandolapril is thought to be through the renin-angiotensin-aldosteron system, trandolapril is effective in low renin hypertension also ([@b4]). Verapamil, an L-type calcium channel blocker, exerts its pharmacological effect by blocking the calcium influx through calcium channel. This effect leads to dilatation of peripheral vessels, thereby decreasing systemic vascular resistance and blood pressure. It also dilates coronary blood vessels ([@b42]).

Trandolapril/verapamil SR is an oral fixed-dosed combination of slow release verapamil hydrochloride, and an immediate-release formulation of trandolapril. It is indicated in the treatment of hypertension in a patient who requires more than one agent to achieve blood pressure target. Studies of verapamil with various ACE inhibitors indicate that the combination should be the therapy of choice in hypertensive patients with diabetes or nephropathy ([@b32]; [@b10]; [@b21]). The complementary pharmacological action of ACE inhibitor and calcium antagonist on efferent and afferent arterioles also results in a beneficial effect on glomerular function. It also exerts additive inhibition of sodium reabsorption via inhibition of aldosterone secretion and a direct tubular effect. The combination of trandolapril and verapamil may also provide additional benefit in inducing the regression of left ventricular hypertrophy ([@b74]; [@b49]). Combination therapy also significantly increases left ventricular ejection fraction and left ventricular wall motion index in hypertensive patients ([@b74]) and duration of exercise time in patients with coronary heart disease and left heart failure. It also leads to an improvement in the ratio of exercise to rest rate-pressure product and a decrease in the number of angina attacks ([@b74]; [@b49]). The trandolapril/verapamil treatment was also found to reduce incidence of cardiac events in comparison with trandolapril therapy in patients with congestive heart failure after acute myocardial infarction ([@b33]). The combination therapy significantly reduced death, re-infarction, unstable angina, or readmission due to increasing congestive heart failure. Similarly, the combination therapy was also found to have a positive effect on aortic elastic properties ([@b19]; [@b70]; [@b52]). In the patients with hypertension and diabetes mellitus, trandolapril/verapamil combination does not adversely affect glucose and lipid metabolism ([@b28]; [@b58]; [@b35]). Rather, data from short-term and long-term studies indicate that ACE inhibitors may actually improve insulin sensitivity and decrease the risk of hypertensive diabetic patients ([@b10]; [@b68]; [@b62]). As worsening/inadequate glycemic control has been shown to be a strong risk factor for both micro- and macro-vascular complications in diabetes, antihypertensive drug without adverse effects on glucose metabolism, such as trandolapril/verapamil combination, in hypertensive diabetic patients offers an advantage provided blood pressure control is adequate.

Pharmacokinetics trandolapril/verapamil SR
==========================================

There is no known kinetics interaction between verapamil and trandolapril or trandolaprilate. The single agent pharmacokinetic parameters of these two drugs should be applicable to a combination product also. However, when administered concomitantly, trandolapril increases the peak plasma concentration (C~max~) of verapamil and norverapamil but time to C~max~ (T~max~) remains unaffected ([@b3]).

Trandolapril component
----------------------

The pharmacokinetic parameters of single and multiple doses of trandolapril in healthy volunteers are summarized in [Table 1](#tbl1){ref-type="table"}. However, there are very few data on pharmacokinetics of trandolapril/verapamil in patients with hypertension, more so for the hypertensive diabetic patients. Most of the information is derived from the manufacturer's information ([@b2], [@b3]). After oral administration trandolapril is absorbed rapidly. Although, absorption is 40%--60%, absolute bioavailability of trandolapril is 10% of the oral dose. The absolute bioavailability of trandolaprilate is 70% ([@b4]). Food does not interfere with absorption of the drug. C~max~ of trandolapril after a single oral dose is proportional to the dose administered and occurs at around a half to 1 hour ([@b17]; [@b9]; [@b38]). After the oral dose the C~max~ of the trandolaprilate is dose proportional, but inversely related. T~max~ ranges from 4 to 8 hours ([@b17]; [@b9]; [@b38]). The elimination half-life (t~1/2~) is less than 1 hour for trandolapril, whereas it is about 75 hours for trandolaprilate ([@b17]; [@b9]; [@b38]; [@b60]). Plasma protein binding of both trandolapril and trandolaprilate is more than 80% ([@b4]).

###### 

Pharmacokinetic properties of trandolapril (T) in healthy volunteers

  Dosage     Duration         C~max~[a](#tf1-1){ref-type="table-fn"} (mg/mL)   T~max~[b](#tf1-2){ref-type="table-fn"} (hour)   AUC ng/mL (hour)                                                                T1/2 (hour)
  ---------- ---------------- ------------------------------------------------ ----------------------------------------------- ------------------------------------------------------------------------------- ----------------------------------------------
  T 0.5 mg   Single dose      0.43 (0.1)[\*](#tf1-3){ref-type="table-fn"}      1[\#](#tf1-4){ref-type="table-fn"}              0.4 (0.11)[\*](#tf1-3){ref-type="table-fn"}                                     0.71 (0.08)[\*](#tf1-3){ref-type="table-fn"}
  T 1 mg     Single dose      0.86 (0.1)[\*](#tf1-3){ref-type="table-fn"}      0.5[\#](#tf1-4){ref-type="table-fn"}            0.95 (0.15)[\*](#tf1-3){ref-type="table-fn"}                                    0.74 (0.09)[\*](#tf1-3){ref-type="table-fn"}
  T 2 mg     Single dose      1.68 (0.33)[\*](#tf1-3){ref-type="table-fn"}     0.5[\#](#tf1-4){ref-type="table-fn"}            1.86 (0.3)[\*](#tf1-3){ref-type="table-fn"}                                     0.68 (0.05)[\*](#tf1-3){ref-type="table-fn"}
  T 4 mg     Single dose      3.32 (0.56)[\*](#tf1-3){ref-type="table-fn"}     0.5[\#](#tf1-4){ref-type="table-fn"}            3.64[\*](#tf1-3){ref-type="table-fn"} (0.44)[\*](#tf1-3){ref-type="table-fn"}   0.76 (0.13)[\*](#tf1-3){ref-type="table-fn"}
  T 2 mg     qd for 10 days   3.19 (0.33)[\*](#tf1-3){ref-type="table-fn"}     1[\#](#tf1-4){ref-type="table-fn"}              3.67 (0.97)[\*](#tf1-3){ref-type="table-fn"}                                    0.68 (0.07)[\*](#tf1-3){ref-type="table-fn"}

C~max~, peak plasma concentration.

T~max~, time to C~max~

Mean.

Median.

Trandolapril is de-esterified to trandolaprilate and this biotransformation takes place mainly in liver ([@b4]). Steady state is reached after about 4 days with multiple oral doses. The effective half-life calculated from accumulation is 16--24 hours ([@b4]). The drug is eliminated from the body predominantly (2/3rd) by fecal route, and one third in the urine. Most of the radioactivity of orally administered radiolabeled trandolapril is excreted after 48 hours and elimination is complete (\~99%) by 7 days ([@b75])

Renal clearance of trandolapril and trandolaprilate exhibit a linear correlation with creatinine clearance and the clearance of trandolapril and trandolaprilate decrease with decreasing renal function ([@b2], [@b4]). Two studies have evaluated the pharmacokinetics of trandolapril and trandolaprilate in patients with chronic renal failure and compared that with volunteers ([@b17]; [@b23]). Compared with normal subjects, the plasma concentration of trandolapril and trandolaprilate are approximately 2-fold greater and renal clearance is reduced by about 85% in patient with creatinine clearance below 30 mL/min and in patients on hemodialysis ([@b4]). In people with moderate to severe hepatic impairment the plasma concentration of trandolapril is increased by 9-fold. The plasma concentration of trandolaprilate is also increased but to a lesser extent. However, inhibition of ACE activity was not affected ([@b2], [@b4]). In people above 65 years of age, the bioavailability of trandolapril is increased by 25%. However, dose adjustment is not recommended ([@b4]; [@b49]).

Verapamil component
-------------------

Similar to the immediate-release formulation, approximately 90% of the administered sustained released formulation is absorbed ([@b3]). However, the rate of absorption is delayed. Because of first-pass metabolism of verapamil, the absolute bioavailability of the drug ranges from 20% to 35% ([@b1], [@b3]). Following administration of verapamil SR 240 mg, the mean peak plasma concentration is reached at 5 hours, while that of its active metabolite norverapamil in around 6 hours ([@b1], [@b4]). Steady state plasma concentration is reached 3--4 days after multiple oral doses of verapamil. Verapamil is 90% bound to plasma proteins ([@b4]). Verapamil undergoes extensive first-pass metabolism in the liver by the P450 cytochrome system ([@b2]). Out of 12 metabolites of verapamil, except the primary active metabolite norverapamil, all other metabolites are present in trace amount ([@b1]). The mean elimination half-life is around 8 hours following multiple doses administration ([@b2]). Most of the administered verapamil is excreted as metabolites in urine (70%) and feces (16%). Three to four percent of administered dose is excreted unchanged ([@b4]). As verapamil undergoes extensive first-pass metabolism, presence of hepatic dysfunction increases the bioavailability and elimination half-life of verapamil ([@b2]). In patient with severe hepatic dysfunction, the clearance is reduced to 30%, while terminal elimination half-life is prolonged by 4--16 hours ([@b1], [@b3]). The pharmacokinetics and elimination of verapamil is not altered by impairment of kidney function ([@b1]; [@b23]). Compared with younger subjects, the bioavailability of verapamil and its metabolite norverapamil is increased by 87% and 77%, respectively, in the elderly ([@b3]).

The trandolapril/verapamil SR combination has not been evaluated in subjects with hepatic or renal impairment. In Europe, it is contraindicated in patients with creatinine clearance of less than 10 mL/min, patients receiving hemodialysis, and patients with severe hepatic impairment, cirrhosis, and ascites ([@b2], [@b3]), while in the US, caution is required to use the combination in patients with hepatic impairment ([@b3]). The special instructions for the individual compounds of the combination of trandolapril and verapamil SR apply to the combination product also ([@b2], [@b3]).

In the elderly, systemic availability of trandolapril/verapamil SR is higher than in younger subjects; therefore blood pressure of some elderly patients might be lowered more than that of younger subjects ([@b2])

Drug interactions
=================

There are several important pharmacodynamic and pharmacokinetic interactions between these two classes of drugs, as with a number of other drugs ([@b1], [@b4]; [@b65]). Although co-prescription of trandolapril/verapamil SR with potassium-sparing diuretics or supplementation of potassium may cause hyperkalemia due to trandolapril, the use of dantrolin with verapamil may cause malignant hyperthermia, and is therefore not recommended ([@b2], [@b4]; [@b65]). A numbers of drugs have a potential pharmacodynamic interaction with trandolapril or verapamil SR; therefore, close monitoring or dose adjustment is needed ([@b1]; [@b2]; [@b4]; [@b4]). Few important pharmacokinetic interactions are tabulated ([Table 2](#tbl2){ref-type="table"}). Trandolapril and its active metabolite do not have clinically significant interactions with furosemide and warfarin ([@b4]). The details of the pharmacodynamic and pharmacokinetic interactions of the combination may be found in the manufacturer's prescribing information ([@b32]; [@b2]; [@b4]; [@b65]).

###### 

Pharmacokinetic interaction between oral trandolapril or verapamil SR and other agents when administered concomitantly (only clinically relevant interactions are cited)

  Effects of verapamil-SR on pharmacokinetics of                 
  -------------------------------------------------------------- ----------------------------------------------------------------------------
  Carbamazapine                                                  Increases the plasma concentration of carbamazapin
  Cyclosporine                                                   Increases the serum concentration of cyclosporine
  Digoxin                                                        Increases the serum concentration of digoxin
  Ethanol                                                        Verapamil decreases the elimination of ethanol
  Metoprololo/propanolol                                         Verapamil decreases the clearance
  Quinidine                                                      Increases the serum concentration of quinidine
  **Effects of trandolapril on**                                 
  Lithium                                                        Trandolapril (ACE inhibitors) increase serum concentration of lithium
  **Effects of other agents on verapamil SR pharmacokinetics**   
  Cimetidine                                                     Increase in verapamil clearance is possible
  Erythromycin                                                   Increases plasma level of verapamil due to inhibition of CYP3A4 inhibition
  Grapefruit juice                                               Increases plasma concentration of verapamil
  Phenobarbitone                                                 Increases verapamil clearance
  Rifampicine                                                    Decreases verapamil bioavailability due to CYP3A4 induction
  Ritonavir                                                      Increases plasma level of verapamil due to inhibition of CYP3A4 inhibition
  **Effects of other agents on trandolapril pharmacokinetics**   
  Antacids                                                       Decreases the bioavailability of trandolapril

Therapeutic efficacy
====================

The antihypertensive efficacy of trandolapril/verapamil SR has been evaluated extensively in large randomized, double-blind or open-labeled blinded endpoint, multicenter studies ([@b24]; [@b25]; [@b69]; [@b72]; [@b37]; [@b45]). In the INVEST trial ([@b45]) a verapamil SR-based treatment strategy that included trandolapril in most patients was effective in reducing the primary outcome in hypertensive patients with coronary artery disease ([@b45]). Several subgroup analyses of INVEST ([@b11]; [@b39]; [@b50]) have been published. Of note, the risk of new onset diabetes was lower in those receiving verapamil SR and trandolapril therapy. INVEST was a randomized, open-label, blinded, endpoint study that involved 22,576 patients aged ≥50 years with hypertension and coexisting coronary artery disease (CAD). A total of 16,176 patients were non-diabetic hypertensives with CAD at the time of entry to the trial. The primary outcome -- all-cause mortality, non-fatal stroke, and non-fatal myocardial infarction -- was compared between two treatment strategies: a calcium channel blocker (verapamil SR)-based strategy and beta blocker (atenolol)-based startegy. As most older hypertensives need two or more antihypertensive drugs to control blood pressure, INVEST was intended to compare the multidrug strategies rather than individual agents. To reach the blood pressure goals targeted according to JNC VI at the time of initiation of the trial, adding sequentially prespecified antihypertensive medications to both treatment arms was allowed in the trial. The verapamil arm allowed for the addition of the ACE inhibitor trandolapril or of a co-formulated tablet containing verapamil SR and trandolapril. The diuretic hydrochlorothiazide could then be added if needed. The beta-blocker arm allowed for the addition of hydrochlorothiazide, with trandolapril added as required to reach goal. ACE inhibitor therapy was recommended for all patients with diabetes or renal disease, regardless of treatment strategy.

Among the patients who did not have diabetes at baseline (8098 in the verapamil SR group and 8078 in the atenolol group), the new onset of diabetes was significantly lower (7.03%) in the verapamil SR/trandolapril treatment group in comparison with those on the atenolol/hydroclorothiazide treatment group (8.23%) ([Figure 1](#fig1){ref-type="fig"}). Treatment with hydrochlorothiazide 25 mg daily was associated with new diabetes in both strategies, whereas increased exposure to the ACE inhibitor trandolapril in verapamil SR strategy appeared to be associated with more protection from the atenolol/hydrochlorothiazide strategy ([@b5]). However, it is difficult to draw a conclusion about the contribution of any single agent because the trial was a comparison of both arms with more than one drug regimen ([@b6]). So it is also not possible to evaluate the independent role of verapamil in INVEST, and it cannot be excluded that the benefit is driven by the trandolapril alone, as it is more likely that the ACE inhibitor prevents diabetes by blocking the renin angiotensin system. While antihypertensive treatment strategy in the diabetes cohort of the INVEST trial was compared between the verapamil SR-based (n = 3169) treatment arm and the atenolol-based (n = 3231) treatment arm, there was no significant difference in the primary outcome between these two treatment groups.

![Among the patients who did not have diabetes at baseline (8098 in the verapamil SR group and 8078 in the atenolol group) addition of trandolapril in verapamil SR strategy was associated with more protection from the development of new onset diabetes than that in the atenolol/hydrochlorothiazide strategy arm. When trandolapril 2 mg was added to verapamil 180 mg and trandolapril 4 mg to verapamil 240 mg the hazard ratio for development of new onset diabetes was 0.56 (0.98--1.64, confidence interval \[CI\] 95%), and 0.58 (0.44--0.78, CI 95%) respectively.](vhrm0304-453-01){#fig1}

[@b12] reported for the first time that combination of a non-dihydorcalcium channel blocker (verapamil) with an ACE inhibitor (trandolapril) achieved better proteinuria reduction in comparison with either agent alone in a randomized, open-labeled, parallel group study. Mean arterial pressure was lower by 3--4 mmHg in the combination group than in the group receiving either agent alone. The effect of combinations of antihypertensive drugs on metabolic control and albuminuria in type 2 diabetic patients has also been studied in the TRAVEND trial. The group of patients receiving the verapamil/trandolapril combination had better metabolic control than enalapril/hydrochlorothiazide group (0.45% difference in HbA1c levels; p = 0.04) ([@b28]). The efficacy related to reduction of albuminuria and blood pressure was comparable in both groups.

A fixed combination of trandolapril/verapamil was compared with trandolapril alone or placebo to attain the required blood pressure goal in previously untreated type 2 diabetic patients presenting with either high normal blood pressure or first stage of isolated hypertension in a randomized, double-blind, placebo-controlled, comparative multicenter study ([@b57]). A total of 393 patients completed the study. Blood pressure reduction was better in patients treated with either trandolapril or fixed combination of verapamil/trandolapril than in the placebo group. The mean difference in systolic blood pressure from placebo was 7.1 mmHg (3.3--10.9, 95% CI, p \< 0.001) for trandolapril and 7.8 mmHg (3.9--11.6, 95% CI, p \< 0.001) for the fixed-dose combination group with no statistically significant difference between the two groups. Combination treatment was also more effective in reducing the diastolic blood pressure than placebo. No significant difference was found between the fixed-combination verapamil/trandolapril and trandolapril with regards to control of systolic blood pressure, but diastolic blood pressure control was significantly higher in the fixed-combination verapamil/trandolapril group (88%) when compared with trandolapril alone (79.1%) or placebo (63.5%).

The issues of metabolic effects of antihypertensive therapy on diabetic patients were also evaluated in various trials. There is increasing concern regarding the metabolic effects of antihypertensive drug therapy and their impact on cardiovascular risk reduction resulting from the treatment of hypertension ([@b61]). Studies by [@b16] have indicated that ACE inhibitors improve glucose use and insulin sensitivity in hypertensive patients with type 2 diabetes. The metabolic, antihypertensive, and albuminuria-modifying effects of the trandolapril/verapamil combination compared with those of a β-blocker low-dose diuretic combination (atenolol/chlortalidone) in hypertensive type 2 diabetic patients was investigated in 2 separate studies ([@b58]; [@b56]). The two approaches produced similar decrease in mean supine clinic blood pressure (BP), upright clinic BP, and ambulatory daytime BP. The trandolapril/verapamil combination was found to be metabolically neutral, while the atenolol/chlortalidone combination further aggravated insulin resistance. This indicates that the trandolapril/verapamil combination is a potentially valuable therapy for hypertension accompanying type 2 diabetes, since the benefits of the ACE inhibitor may be amplified by providing superior BP control with added renal and cardiovascular protection.

In a further study, in patients with hypertension and type 2 diabetes, the effects of either fixed-dose combination of trandolapril/verapamil or a combination of atenolol/clorthalidone, on glycosylated hemoglobin (HbA1c) and other metabolic parameters was evaluated. The trandolapril/verapamil group had lower HbA1c concentration compared with patients treated with atenolol/chlortalidone (7.8 vs 8.6%; p = 0.001), demonstrating a significantly more favorable profile on glycemic control ([@b35]). The data of all these studies make the combination trandolapril/verapamil very attractive in hypertensive diabetic patients.

The high prevalence of diabetes, the increased rate of cardiovascular and renal complications, and the beneficial effect of antihypertensive therapy make primary prevention efforts a high priority. Hypertensive diabetes individuals are at high risk of developing cardiovascular disease and progression to ESRD. Hypertension, in addition, to obesity, hyperglycemia, dyslipidemia, and microalbuminuria, is a component of the metabolic syndrome -- a syndrome sustained by decreased insulin activity that almost invariably precedes or accompanies the onset of type 2 diabetes and is independently associated with excessive cardiovascular morbidity and mortality ([@b29]). Now, numerous studies have documented that the albumin excretion in the urine above the normal range is clearly associated with heightened risk of cardiovascular events and further progression of kidney disease. Every year 2%--5% of the type 2 diabetic patients develop microalbuminuria ([@b30]; [@b6]) and, unlike type 1 diabetes mellitus, it is seldom reversible in type 2 diabetic patients and progresses to overt proteniuria in 20%--40% of patients ([@b40]; [@b44]). Forty to fifty percent of patients with type 2 diabetes having microalbuminuria eventually die of cardiovascular disease ([@b6]). Therefore, it is quite reasonable to target the treatment to modify the development of microalbuminuria at early stage of diabetes, as well as control blood pressure in hypertensive diabetes to limit the cardiovascular and renal disease. The Bergamo Nephrologic Diabetes Complications Trial (BENEDICT \[[@b53]\]) was designed to test the hypothesis that combination therapy with the ACE inhibitor trandolapril and non-dihydropyridine calcium channel blocker verapamil reduced the incidence of persistent microalbuminuria in hypertensive type 2 diabetic patients with no clinical evidence of diabetic nephropathy. The secondary objectives involved comparisons of trandolapril or verapamil with placebo in providing renal protection in hypertensive diabetic patients.

In the BENEDICT study a total of 1204 patients with hypertension (systolic or diastolic blood pressure more than 130 or 85 mmHg, respectively, or concomitant antihypertensive therapy), type 2 diabetes and normal urinary excretion (\<20 mg/min in at least 2 of 3 consecutive overnight urine collections) were randomly assigned, using 2 × 2 factorial design, to receive in a double blind manner for at least 3 years one of the following study drugs: I, a non-dihydropyridine calcium channel blocker (ndCCB): verapamil SR, 240 mg/day; II, an ACE inhibitor: trandolapril 2 mg/day; III, the combination of verapamil SR, 180 mg/day plus trandolapril 2 mg/day: VeraTran; and IV, placebo. The target blood pressure after randomization and throughout the whole study period was less than 130/80 mmHg for all the treatment groups. Other antihypertensive drugs (with the exception of renin-angiotensin system inhibitors and ndCCBs different from the study drugs) could be used to achieve and maintain systolic and diastolic blood pressure consistently below 140/90 mmHg (subsequently amended to below 130/80 mmHg at randomization and below 120/80 on follow up ([@b67]; [@b53]). Baseline characteristics and simultaneous treatments of patients randomized in the four treatment groups were comparable. Patients were to be maintained in metabolic control (target HbA1c \<7%). Patients were excluded if they had concomitant non-diabetic renal disease or heart failure (NYHA-IV or on ACE inhibition therapy), cardiovascular events (stroke, transient ischemic attack, unstable angina) in the last 3 months before randomization, severe hypertension (diastolic blood pressure ≥115), systemic diseases, or any major clinical condition that jeopardize study participation. Patients with specific contraindication to the study drug were also excluded.

The BENEDICT study found that over 4 years of follow-up, trandolapril alone, or trandolapril/verapamil SR (VeraTran) delayed the onset of microalbuminuria by a factor of 2.6 and 2.1, respectively, while verapamil had no significant effect ([@b53]). Thus the incidence of microalbuminuria versus placebo was reduced by 60% (hazard ratio \[95% CI\]: 0.39 \[0.21--0.73\]) with VeraTran and by 50% with trandolapril (Hazard ratio \[95% CI\]: 0.49 \[0.27--0.90\]), but was not appreciably affected by verapamil ([Figure 2](#fig2){ref-type="fig"}). This indicates that the apparent advantage of ACE inhibitors (trandolapril in BENEDICT) over other antihypertensive agents includes also a protective effect on the kidney against the development of microalbuminuria, at least in type 2 diabetic patients. Moreover, finding that this effect was significant even after adjustment for baseline and follow-up systolic and diastolic blood pressure provided evidence of a specific renoprotective effect of ACE inhibition therapy against the development of microalbuminuria which was independent of the level of achieved blood pressure control.

![The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT) is a multicenter double-blind, randomized study designed to assess whether the angiotensin converting enzyme inhibitor trandolapril and the non-dihydropyridine calcium-channel blocker verapamil, alone or in combination, prevent microalbuminuria in subjects with hypertension, type 2 diabetes mellitus, and normal urinary albumin excretion. The Kaplan-Meier curves show the percentages of subjects with microalbuminuria during treatment with trandolapril/verapamil or placebo. The difference between the two groups adjusted for pre-specified baseline covariates was significant (p = 0.01) according to the accelerated failure (A.F.)-time model.\
**Abbreviations:** DBP, diastolic blood pressure; SBP, systolic blood pressure.](vhrm0304-453-02){#fig2}

Recently the post-hoc analysis of the BENEDICT trial was reported ([@b55]). Of 1204 patients in the original study cohort, 1180 patients were included in the post-hoc analysis. Twenty-four patients were excluded because either they reached an endpoint, stopped regular study follow-up or blood pressure recording was inadequate for the analysis. Overall, the systolic blood pressure was decreased 6.5 ± 7.63% and diastolic blood pressure was decreased 6.4 ± 7.47% from baseline to follow-up. Baseline mean arterial pressure (MAP) and pulse pressure were 108.6 ± 8.33 mmHg and 63.3 ± 12.64 mmHg: they decreased by 6.5 ± 6.83% and 5.3 ± 14.70%, to 101.2 ± 6.47/58.9 ± 9.99 mmHg on follow-up. The findings from a post-hoc analysis suggest that in patients with type 2 diabetes and hypertension, effective blood pressure reduction has a specific and independent protective effect against the development of microalbuminuria. Nevertheless, trandolapril had a further protective effect, in particular when blood pressure was poorly controlled, whereas the ndCCB therapy was ineffective at any level of achieved blood pressure ([Figure 3](#fig3){ref-type="fig"}). The finding that the risk of developing microalbuminuria was not associated with baseline blood pressure provided consistent evidence that the lower incidence of microalbuminuria observed with more effective blood pressure reduction reflected a benefit of treatment and not simply less severe hypertension at study entry ([Figure 4](#fig4){ref-type="fig"}). Therefore, these results extend to the very early stages of diabetic renal disease previous evidence of a renoprotective effect of blood pressure control in people with diabetes and established nephropathy ([@b40]; [@b26]; [@b13]; [@b48]; [@b51]). Of interest, patients with systolic, diastolic, mean blood pressure, and pulse pressure reduction above the medians compared with those with corresponding blood pressure reductions below the medians, were more frequently on ACE inhibitor therapy with trandolapril/verapamil or trandolapril alone and, on the contrary, were less frequently on treatment with concomitant antihypertensive medications such as diuretics, betablockers, ndCCBs, and sympatholytic agents ([Table 3](#tbl3){ref-type="table"}). The risk reduction achieved by ACE inhibitor therapy in patients with systolic, MAP, and pulse pressure below the median was significant even after adjustment for baseline covariates and concomitant treatment with ndCCBs. A similar trend was observed for diastolic blood pressure.

![Patients who developed microalbuminuria throughout the study period of the BENEDICT trial according to follow-up systolic blood pressure (SBP). These are patients with type 2 diabetes, arterial hypertension, and normoalbuminuria at baseline. Effective SBP reduction below the median (\<139.16 mmHg) has specific and independent protective effects against the development of microalbuminuria. The risk reduction for microalbuminuria that was achieved by angiotensin converting enzyme inhibitor (ACEi) therapy in patients with follow-up SBP above the median (≥139.16 mmHg) was highly significant even after adjustment for baseline covariates and concomitant treatment with non-dihydropyridine calcium channel blockers. Thus ACEi therapy had a further protective effect, in particular when SBP was less effectively controlled (inset).](vhrm0304-453-03){#fig3}

![In the BENEDICT study, the extent of systolic blood pressure (SBP) reduction had a specific and independent effect against the development of microalbuminuria. Angiotensin converting enzyme inhibitor (ACEi) therapy had a further protective effect, in particular when the SBP was less effectively controlled (inset).](vhrm0304-453-04){#fig4}

###### 

Number (%) of patients on different antihypertensive treatments on trial according to systolic blood pressure (SBP), diastolic BP (DBP), mean arterial pressure (MAP), and pulse pressure reduction above or below the median

                  Systolic BP   Diastolic BP                                    MAP          Pulse pressure                                                                                                                
  --------------- ------------- ----------------------------------------------- ------------ ------------------------------------------------- ------------ ------------------------------------------------- ------------ ---------------------------------------------
  ACEi YES        319 (53.9)    273 (46.4)[\*](#tf3-3){ref-type="table-fn"}     323 (54.6)   269 (45.8)[\*\*](#tf3-2){ref-type="table-fn"}     316 (53.3)   276 (47.0)[\*](#tf3-3){ref-type="table-fn"}       317 (53.6)   275 (46.8)[\*](#tf3-3){ref-type="table-fn"}
  ndCCB YES       293 (49.5)    297 (50.5)                                      300 (50.7)   290 (49.3)                                        303 (51.1)   287 (48.9)                                        283 (47.8)   307 (52.2)
  VeraTran        158 (26.7)    135 (23.0)                                      157 (26.5)   136 (23.1)                                        160 (27.0)   133 (22.7)                                        153 (25.8)   140 (23.8)
  Trandolapril    161 (27.2)    138 (23.5)                                      166 (28.0)   133 (22.6)[\*](#tf3-3){ref-type="table-fn"}       156 (26.3)   143 (24.4)                                        164 (27.7)   135 (23.0)
  Verapamil       135 (22.8)    162 (27.6)                                      143 (24.2)   154 (26.2)                                        143 (24.1)   154 (26.2)                                        130 (22.0)   67 (28.4)[\*](#tf3-3){ref-type="table-fn"}
  Placebo         138 (23.3)    152 (26.0)                                      126 (21.3)   165 (28.1)[\*\*](#tf3-2){ref-type="table-fn"}     134 (22.6)   157 (26.8)                                        145 (24.5)   146 (24.8)
  Diuretic        97 (16.4)     132 (22.5)[\*](#tf3-3){ref-type="table-fn"}     95 (16.1)    134 (22.8)[\*\*](#tf3-2){ref-type="table-fn"}     98 (16.5)    131 (22.3)[\*](#tf3-3){ref-type="table-fn"}       105 (17.7)   124 (21.1)
  Beta-blocker    44 (7.4)      59 (10.0)                                       47 (7.9)     56 (9.5)                                          45 (7.6)     58 (9.9)                                          51 (8.6)     52 (8.8)
  dCCB            142 (24.0)    185 (31.5)[\*\*](#tf3-2){ref-type="table-fn"}   145 (24.5)   182 (31.0)[\*](#tf3-3){ref-type="table-fn"}       137 (23.1)   190 (32.4)[\*\*\*](#tf3-1){ref-type="table-fn"}   160 (27.0)   167 (28.4)
  Sympatholytic   265 (44.8)    292 (49.7)                                      250 (42.2)   307 (52.2)[\*\*\*](#tf3-1){ref-type="table-fn"}   256 (43.2)   301 (51.3)[\*\*](#tf3-2){ref-type="table-fn"}     276 (46.6)   281 (47.8)
  agent                                                                                                                                                                                                                    

p ≤ 0.001

p ≤ 0.01

p \< 0.05 versus below.

**Abbreviations:** ACEi, angiotensin converting enzyme inhibitor; dCCB, dihydropyridine calcium channel blocker; ndCCB, non-dihydropyridine calcium channel blocker.

A major practical problem, however, is that the recommended target of 130 mmHg for systolic blood pressure ([@b20]) is seldom achievable in patients with type 2 diabetes, even when several blood-pressure-lowering medications are used in combination ([@b18]; [@b15]; [@b53], [@b54]). Sixty-two percent of BENEDICT patients received one or more antihypertensive drugs in addition to the study drugs and all of them were recommended a low sodium intake. Despite this, only 14% of them achieved a systolic blood pressure of 130 mmHg or less. However, of note the highest proportion of patients on target was observed among those on combined trandolapril/verapamil treatment who, notably, less frequently required concomitant treatment with other antihypertensive medications. This is of great significance as hypertension is an independent and strong risk factor for cardiovascular disease events and renal disease progression in diabetic patients with hypertension, and concern for compliance with multiple drugs is an issue. Since microalbuminuria is a strong predictor of kidney failure and cardiovascular morbidity/mortality, the specific protective effect of ACE inhibitor therapy against the development of microalbuminuria should be taken into consideration in treatment guidelines for the practising physician ([@b27]; [@b55]). Indeed, most guidelines recommend any agent in patients with diabetes and hypertension and without nephropathy, and only ACE inhibitors or angiotensin II receptor blockers once nephropathy occurs ([@b43]). This largely rests on data from hypertension trials showing that blood pressure reduction limits cardiovascular morbidity and mortality regardless of the antihypertensive agent used to achieve the target blood pressure, and overlooks that only ACE inhibitors have been proven to reduce the onset of microalbuminuria in hypertensive patients with diabetes. The post-hoc analysis of BENEDICT, consistent with previous evidence from BENEDICT ([@b53]) and other trials ([@b63]), provide the evidence that compared with other agents, ACE inhibitors have an incremental benefit on renal outcomes and so should be the treatment of choice in hypertensive patients with diabetes.

Conclusion
==========

Effective blood pressure control and ACE inhibitor therapy are both key components of cardiovascular and renoprotective treatments in hypertensive type 2 diabetic patients. The combination of an ACE inhibitor and an ndCCB may help achieve optimal blood pressure control while limiting the need for concomitant antihypertensive medications that may adversely affect the metabolic control and the overall cardiovascular risk profile of people with diabetes. Trandolapril/verapamil SR is an effective and well tolerated combination therapy for both patients with hypertension and type 2 diabetes mellitus. In BENEDICT, trandolapril alone, or trandolapril/verapamil delayed the onset of microalbuminuria in more than 40% of patients compared with placebo in hypertensive diabetic patients. The effect of verapamil alone was similar to that of placebo. In the INVEST trial, ndCCB-based treatment strategy, in which most of the patients received ACE inhibitor (trandolapril), was more effective in reducing new onset diabetes in patients 50 years and older with hypertension and CAD. This indicates that the apparent advantage of ACE inhibitors over other antihypertensive agents includes also a protective effect on the kidney against the development of microalbuminuria, at least in type 2 diabetic patients, as well as development of new onset diabetes in hypertensive patients. Because microalbuminuria is a strong predictor of kidney failure and cardiovascular morbidity/mortality, the specific protective effect of ACE inhibition therapy against the development of microalbuminuria should be taken into consideration in the treatment guidelines for the practising physician. Whether an antihypertensive regimen including such a combination drug may effectively limit the excess morbidity and mortality associated with type 2 diabetes is worth investigating in prospective randomized trials.
